Prospective study reports sustained outcomes with Elizaria in atypical haemolytic uraemic syndrome

The 56-week observational findings add longer-term clinical evidence for the eculizumab biosimilar in both complement-inhibitor-naive patients and those previously treated with reference eculizumab.

A prospective, multicentre observational study of 50 patients found that treatment with the eculizumab biosimilar Elizaria maintained haematological control over 56 weeks in atypical haemolytic uraemic syndrome, with normal platelet counts reported in 100% of treatment-naive patients and 96% of previously treated patients by study end.

The findings provide additional real-world evidence relevant to clinicians and healthcare systems considering biosimilar initiation or switching, although the uncontrolled study design limits direct comparisons with reference eculizumab.

Field	Content
Alert Type	Industry Update
Topic	Clinical research; biosimilars
Organisation(s)	Multicentre study investigators; Karger Publishers
Affected Stakeholders	Nephrologists, haematologists, paediatric specialists, hospital formulary committees and healthcare systems involved in treating atypical haemolytic uraemic syndrome
Therapy Area(s)	Nephrology; Haematology; Rare Disease
Geography	Study geography not clearly stated in the accessible abstract; findings published internationally in Nephron
What Happened	A prospective observational study evaluated 56 weeks of routine-practice treatment with Elizaria, an eculizumab biosimilar, in 50 patients aged 1–55 years with atypical haemolytic uraemic syndrome. Of these, 31 patients were complement-inhibitor naive and 19 had previously received eculizumab. By study end, all treatment-naive patients and 96% of previously treated patients had normal platelet counts; 80% of the overall cohort remained free from thrombotic microangiopathy events at week 52. The study was published online on 12 June 2026. (Karger Publishers)
Why It Matters	Long-term evidence is particularly relevant for biosimilars used in rare, life-threatening diseases, where clinicians and formulary decision-makers may require reassurance regarding sustained disease control, safety and immunogenicity. The findings support the continued evaluation of Elizaria as an option for both treatment initiation and switching, but they do not establish equivalence with reference eculizumab because the study had no randomised comparator group. (Karger Publishers)
Supporting Context	Atypical haemolytic uraemic syndrome is driven by uncontrolled complement activation and can cause thrombotic microangiopathy, haemolysis and progressive kidney injury. Eculizumab inhibits terminal complement activity and is an established treatment, while biosimilar development may broaden procurement and treatment options where products are approved and available. (Center for Biosimilars)
Who Is Most Affected	Clinicians managing aHUS and organisations making formulary or procurement decisions are most directly affected, particularly where a biosimilar switch or first-line biosimilar use is being considered.
Industry Impact	The results add to the evidence base that may inform biosimilar adoption, formulary reviews and pharmacovigilance planning. Their practical effect will depend on local regulatory approval, pricing, reimbursement and the availability of further comparative and longer-term data.
Key Takeaway	Elizaria maintained broadly stable haematological outcomes over 56 weeks in a mixed aHUS population, providing supportive but non-comparative evidence for longer-term biosimilar use.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com